SG Americas Securities LLC Grows Position in Hologic, Inc. $HOLX

SG Americas Securities LLC grew its stake in Hologic, Inc. (NASDAQ:HOLX) by 1,662.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,358 shares of the medical equipment provider’s stock after buying an additional 78,627 shares during the quarter. SG Americas Securities LLC’s holdings in Hologic were worth $5,626,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Chung Wu Investment Group LLC bought a new position in shares of Hologic during the 2nd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd boosted its position in shares of Hologic by 193.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the period. SJS Investment Consulting Inc. boosted its position in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 362 shares during the period. Loomis Sayles & Co. L P purchased a new stake in shares of Hologic in the second quarter worth $33,000. Finally, Cromwell Holdings LLC raised its position in shares of Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 436 shares during the period. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling at Hologic

In related news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director owned 47,336 shares in the company, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.88% of the company’s stock.

Hologic Trading Down 0.0%

Shares of HOLX stock opened at $74.87 on Friday. The company has a current ratio of 3.75, a quick ratio of 3.06 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $16.69 billion, a price-to-earnings ratio of 30.19, a price-to-earnings-growth ratio of 2.12 and a beta of 0.69. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.34. The stock’s 50-day moving average price is $74.64 and its 200-day moving average price is $69.86.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a return on equity of 20.13% and a net margin of 13.80%.The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter last year, the business posted $1.01 EPS. The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. Equities research analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st. Mizuho lowered Hologic from an “outperform” rating to a “neutral” rating and upped their price objective for the stock from $70.00 to $78.00 in a research note on Thursday, October 23rd. BNP Paribas cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price for the company. in a research report on Friday, November 21st. Stephens downgraded Hologic from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $78.00 to $76.00 in a research note on Wednesday, October 22nd. Finally, BNP Paribas Exane downgraded Hologic from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a research note on Friday, November 21st. Four equities research analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and an average target price of $79.29.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.